PDCD1 and cancer: However, O’Connor et al. (2018) reported rapid adoption of novel cancer therapeutics, specifically immune checkpoint inhibitors of programmed cell death 1 protein (anti-PD-1 agents), immediately after FDA approval in the United States [12].